Clinical and pharmacological group: & nbsp

Glucocorticosteroids

Included in the formulation
  • Rectodel®
    suppositories rect. 
  • АТХ:

    H.02.A.B.07   Prednisone

    Pharmacodynamics:

    Glucocorticosteroid, has anti-inflammatory, anti-allergic, anti-shock, immunosuppressive effect.

    Interaction with intracellular glucocorticoid receptors leads to the formation of dimers of the glucocorticoid-glucocorticoid receptor complex.

    The steroid hormone complex with the receptor is transported to the nucleus of the cell. In the nucleus this complex interacts with effector elements localized on the acceptor sites of the chromatin (genes). As a result of the interaction, stimulation or inhibition of gene expression occurs; this leads to a change in the synthesis of matrix RNA and proteins.

    The anti-inflammatory effect of prednisone is due to several factors. 1. The drug induces the synthesis of lipocortin, which inhibits the activity of phospholipase A2. Inhibition of phospholipase-mediated A2 hydrolysis of membrane phospholipids of damaged tissues prevents the formation of arachidonic acid. The disruption of the formation of arachidonic acid actually means inhibition of the synthesis of prostaglandins, since arachidonic acid is a substrate for further metabolism along the cyclooxygenase pathway, and also along the lipoxygenase pathway, with appropriate inhibition of leukotriene synthesis.

    2.The anti-inflammatory effect of prednisone is potentiated by its ability to inhibit the expression of COX-2 genes, which also leads to a decrease in the synthesis of prostaglandins in the inflammatory focus, including pro-inflammatory prostaglandins E2 and I2.

    3. Prednisone inhibits the expression of molecules of intercellular adhesion in the endothelium of blood vessels, violating the penetration of neutrophils and monocytes into the focus of inflammation. After the introduction of glucocorticoids, an increase in the concentration of neutrophils in the blood (due to their entry from the bone marrow and the restriction of migration from the blood vessels) is noted. This causes a decrease in the number of neutrophils in the site of inflammation.

    Prednisone inhibits the transcription of cytokine genes that stimulate the inflammatory and immune response (IL-1, IL-2, IL-6, IL-8), as well as tumor necrosis factor (and some others). Also, a decrease in the transcription rate and an increase in the degradation of the receptor genes for IL-1 and IL-2, inhibition of the transcription of the metalloproteinase (collagenase, elastase, etc.) genes involved in the enhancement permeability of the vascular wall, in the processes of scarring and destruction of cartilaginous tissue in diseases of the joints.

    Immunosuppressive action is due to inhibition of transcription of DNA encoding the main histocompatibility complex, pro-inflammatory cytokines (IL-1, IL-2) and inhibition of proliferation of T-lymphocytes. It leads to a decrease in the number of T-lymphocytes and their influence on B-lymphocytes, inhibits the production of immunoglobulins. Reduces formation and increases the breakdown of the components of the compliment system.

    The antiallergic effect is associated with the inhibition of the synthesis of mediators of allergy, degranulation of mast cells and the release of mediators of allergy, in connection with which it is effective for allergic reactions of immediate type

    Restores the sensitivity of adrenoreceptors to catecholamines. Accelerates the breakdown of proteins and reduces their concentration in the plasma, inhibits the utilization of glucose by peripheral tissues and stimulates gluconeogenesis in the liver, potentiates the formation of enzyme proteins in the liver, erythropoietin, fibrinogen, surfactant, lipomodulin. It leads to the redistribution of fat, increases the formation of triglycerides and higher fatty acids. Reduces absorption and potentiates the excretion of calcium; delays sodium and water.

    The mechanism of the antishock effect of prednisolone is associated with a decrease in the synthesis of the platelet activating factor (a shock mediator), as well as a decrease in extra-neuronal capture and an increase in the pressor effect of catecholamines.

    Influences on various kinds of a metabolism: raises a level of a glucose in a blood, promotes redistribution of a fatty fabric, promotes a delay of ions of sodium and water, increases arterial pressure. Modulates inflammatory processes in connective tissue and reduces the likelihood of scar tissue formation.

    Pharmacokinetics:

    Absorbed in the gastrointestinal tract. Bioavailability - 80 ± 11%. The volume of distribution is 0.97 ± 0.11 l / kg. Maximum concentration in blood plasma is observed after 1-2 hours Metabolized in the liver to the active metabolite - prednisolone. The connection with plasma proteins is 90%, biotransformed in the liver, bronchi and kidneys. Excreted mainly by the kidneys in unchanged form.

    With rectal administration, more than 20% of the drug is absorbed. This amount can increase if there is inflammation or lesions of the rectal mucosa.

    Indications:
    • Rheumatism, rheumatoid arthritis.
    • Dermatomyositis.
    • Nodular periarteritis.
    • Bechterew's disease.
    • Scleroderma.
    • Bronchial asthmama, allergic diseases.
    • False groats in children.
    • Acute insufficiency of the adrenal cortex.
    • Addison's disease.
    • Adrenogenital syndrome.
    • Hepatitis.
    • Hypoglycemic conditions.
    • Hepatic coma.
    • Lipoid nephrosis.
    • Agranulocytosis.
    • Lymphogranulomatosis.
    • Different forms of leukemia.
    • Thrombocytopenic purpura.
    • Chorea.
    • Hemolytic anemia.
    • Pemphigus.
    • Itching.
    • Eczema.
    • Exfoliative dermatitis.
    • Scrapes.
    • Psoriasis.
    • Seborrheic dermatitis.
    • Erythroderma.
    • Lupus erythematosus.
    • Alopecia.

    II.C81-C96.C81   Hodgkin's disease [lymphogranulomatosis]

    III.D55-D59.D59   Acquired hemolytic anemia

    III.D65-D69.D69.3   Idiopathic thrombocytopenic purpura

    III.D70-D77.D70   Agranulocytosis

    IV.E15-E16.E16.1   Other forms of hypoglycemia

    IV.E20-E35.E25   Adrenogenital disorders

    IV.E20-E35.E27.1   Primary insufficiency of the adrenal cortex

    IV.E20-E35.E27.2   Addison's Crisis

    X.J40-J47.J45   Asthma

    XI.K70-K77.K72   Hepatic failure, not elsewhere classified

    XI.K70-K77.K73   Chronic hepatitis, not elsewhere classified

    XII.L10-L14.L10   Pemphigus [pemphigus]

    XII.L20-L30.L20.8   Other atopic dermatitis

    XII.L20-L30.L21   Seborrheic dermatitis

    XII.L20-L30.L23   Allergic contact dermatitis

    XII.L20-L30.L24   Simple irritant contact dermatitis

    XII.L20-L30.L26   Exfoliative dermatitis

    XII.L20-L30.L28.0   Simple chronic lichen

    XII.L20-L30.L28.1   Scabby nodosum

    XII.L20-L30.L29   Itching

    XII.L20-L30.L30.0   Coin-like eczema

    XII.L40-L45.L40   Psoriasis

    XII.L50-L54.L53   Other erythematous conditions

    XII.L60-L75.L63   Alopecia areata

    XII.L80-L99.L93.0   Discoid lupus erythematosus

    XIII.M05-M14.M05   Seropositive rheumatoid arthritis

    XIII.M30-M36.M30   Nodular polyarteritis and related conditions

    XIII.M30-M36.M33   Dermatopolymiositis

    XIII.M30-M36.M34   Systemic sclerosis

    XIII.M45-M49.M45   Ankylosing spondylitis

    XIII.M70-M79.M79.0   Rheumatism, unspecified

    XVIII.R50-R69.R57   Shock, not elsewhere classified

    XIX.T66-T78.T78.2   Anaphylactic shock, unspecified

    XIX.T66-T78.T78.4   Allergy, unspecified

    XIX.T79.T79.4   Traumatic shock

    XIX.T80-T88.T81.1   Shock during or after the procedure, not elsewhere classified

    Contraindications:
    • Stomach ulcer and duodenal ulcer in the acute phase
    • Disease of Itenko-Cushing
    • Osteoporosis
    • Tendency to thromboembolism
    • Renal insufficiency
    • Systemic mycoses
    • Severe arterial hypertension
    • Vaccination period
    • Active form of tuberculosis
    • Viral infections
    • Active form of tuberculosis
    • The productive symptomatology of mental illnesses
    • Glaucoma
    • Hypersensitivity
    Carefully:

    There may be withdrawal syndrome, as well as an exacerbation of the disease, for which the drug is prescribed; diabetes mellitus, nonspecific infections, latent forms of tuberculosis, pregnancy (especially I trimester).

    Pregnancy and lactation:

    Category FDA - C. Adequate and well-controlled studies in humans have not been conducted. In pharmacological doses, it causes placental insufficiency, fetal body weight deficiency, stillbirth. Teratogenic effect is not confirmed. Hormone replacement therapy does not adversely affect the fetus and the newborn. Animal studies revealed an increase in the incidence of cleft palate, placental insufficiency, spontaneous abortion, and delayed intrauterine development of the fetus.

    Penetrates into breast milk. There are no violations. When appointing physiological or low pharmacological doses (equivalent to not more than 25 mg of cortisone or 5 mg of prednisone) do not cause disturbances in the development of the child. Prescribe higher doses are not recommended because of possible disabilities in the development of the child (growth retardation, impaired production of its own glucocorticoids).

    Dosing and Administration:

    Dosing regimen is individual. The initial dose for adults - 20-30 mg (if necessary, can be from 15-100 mg) per day, maintaining a dose of 5-10 mg (5-15 mg) per day. The decrease in the daily dose should be gradual. The initial dose for children is 1-2 mg / kg per day in 4-6 doses, maintaining a dose of 300-600 mcg / kg per day.

    Rectal: children are given one suppository per day for cupping coughing and suffocation attacks (corresponding to 100 mg of prednisolone). If necessary, another administration of the suppository is possible on this day or on the second day. The total dose should not exceed two suppositories per day (corresponding to 200 mg of prednisone).

    Side effects:

    From the side nervous system: Steroid cataract, mental disorders, latent glaucoma.

    From the side endocrine system: weight gain, Itenko-Cushing syndrome, adrenocortical depletion, steroid diabetes, negative nitrogen balance, hyperglycemia.

    From the side water-electrolyte balance: hypokalemia, hypernatremia.

    From the side of cardio-vascular system: arterial hypertension.

    From the side gastrointestinal tract: ulcerogenic effect, increased acidity of gastric juice.

    From the side musculoskeletal system: aseptic necrosis of bones, osteoporosis.

    With rectal administration: itching, burning, irritation at the injection site. Allergic reactions are possible.

    Overdose:

    Symptoms: increased side effects, vomiting, nausea, sleep disorders, euphoria, depression, agitation.

    Treatment: gradual withdrawal of the drug.

    Interaction:

    Salicylates - increase the likelihood of bleeding.

    Diuretics - violations of electrolyte metabolism.

    Hypoglycemic drugs - reducing the rate of decrease in blood glucose.

    Cardiac glycosides are a risk of glycosidic intoxication.

    Inductors of enzymes (barbiturates, phenytoin, primidon, rifampicin) can reduce the effect of glucocorticosteroids.

    Hypotensive drugs - reducing their effectiveness.

    Rafampicin, barbiturates and phenytoin - decrease in the effect of the drug.

    Hormonal contraceptives, estrogens - enhancing the effect of the drug.

    Glucocorticosteroids can reduce the concentration of salicylates and praziquantel in the blood.

    Antipsychotic drugs, azathioprine, carbutamide - risk of developing cataracts.

    M-holinoblokatory, nitrates, antihistamines, tricyclic antidepressants - increased intraocular pressure.

    The action of insulin, oral hypoglycemic and hypotensive dasgs, as well as oral anticoagulants (coumarin derivatives) can be reduced by simultaneous use of prednisone.

    Increase the risk of side effects of glucocorticosteroids: non-steroidal anti-inflammatory drugs (erosive-ulcerative lesions and bleeding from the gastrointestinal tract), androgens, estrogens, oral contraceptives, steroid anabolics (hirsutism, acne); diuretics and laxatives (hypokalemia).

    In the case of simultaneous use with ACE inhibitors, changes in the blood formula are possible. Possible weakening of the action of growth hormone. Chlorokhin, hydroxychloroquine, mefloquine - increased risk of myopathies and cardiomyopathies.

    Cyclosporine is an increased risk of cerebral cramps.

    Special instructions:

    During treatment, it is necessary to observe the oculist, control blood pressure and water-electrolyte balance, and picture peripheral blood.

    In psoriasis, take under the strict supervision of a doctor.

    When diabetes is used only with absolute indications.

    Impact on the ability to drive vehicles and manage mechanisms not found.

    Instructions
    Up